Literature DB >> 11224520

An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide.

R Pedotti1, D Mitchell, J Wedemeyer, M Karpuj, D Chabas, E M Hattab, M Tsai, S J Galli, L Steinman.   

Abstract

EAE can refer either to experimental autoimmune encephalomyelitis or experimental allergic encephalomyelitis. Although EAE is classically a prototypic T helper 1 (TH1) cell-mediated autoimmune disease, it can also be induced by TH2 cells. Characteristically, the most severe manifestation of allergy, anaphylaxis, is associated with exposure to a foreign antigen that is often derived from medication, insect venom or food. We report here that, after self-tolerance to myelin is destroyed, anaphylaxis may be triggered by a self-antigen, in this case a myelin peptide. "Horror autotoxicus", which was initially described by Ehrlich, may not only include autoimmunity to self, it may also encompass immediate hypersensitivity to self, which leads to shock and rapid death.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11224520     DOI: 10.1038/85266

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  50 in total

Review 1.  Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities.

Authors:  S M Anderton
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

2.  Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination.

Authors:  Rosetta Pedotti; Jason J DeVoss; Sawsan Youssef; Dennis Mitchell; Jochen Wedemeyer; Rami Madanat; Hideki Garren; Paulo Fontoura; Mindy Tsai; Stephen J Galli; Raymond A Sobel; Lawrence Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-07       Impact factor: 11.205

Review 3.  Immune modulating peptides for the treatment and suppression of multiple sclerosis.

Authors:  Ahmed H Badawi; Teruna J Siahaan
Journal:  Clin Immunol       Date:  2012-06-05       Impact factor: 3.969

4.  Multimerized T cell epitopes protect from experimental autoimmune diabetes by inducing dominant tolerance.

Authors:  Eliane Piaggio; Lennart T Mars; Cécile Cassan; Julie Cabarrocas; Maria Hofstätter; Sabine Desbois; Emilie Bergereau; Olaf Rötzschke; Kirsten Falk; Roland S Liblau
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-16       Impact factor: 11.205

5.  Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities.

Authors:  Cassandra E Smith; Stephen D Miller
Journal:  J Autoimmun       Date:  2006-12       Impact factor: 7.094

Review 6.  Development of therapies for autoimmune disease at Stanford: a tale of multiple shots and one goal.

Authors:  Lawrence Steinman
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

7.  A selective role of NKG2D in inflammatory and autoimmune diseases.

Authors:  Nadia Guerra; Kathleen Pestal; Tiffany Juarez; Jennifer Beck; Karen Tkach; Lin Wang; David H Raulet
Journal:  Clin Immunol       Date:  2013-09-14       Impact factor: 3.969

8.  Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice.

Authors:  Judith T Murphy; Andre P Burey; Amy M Beebe; Danling Gu; Leonard G Presta; Taha Merghoub; Jedd D Wolchok
Journal:  Blood       Date:  2014-02-20       Impact factor: 22.113

9.  A GMCSF-neuroantigen fusion protein is a potent tolerogen in experimental autoimmune encephalomyelitis (EAE) that is associated with efficient targeting of neuroantigen to APC.

Authors:  J Lori Blanchfield; Mark D Mannie
Journal:  J Leukoc Biol       Date:  2010-03       Impact factor: 4.962

10.  L.E.A.P.S. heteroconjugate is able to prevent and treat experimental autoimmune myocarditis by altering trafficking of autoaggressive cells to the heart.

Authors:  Daniela Cihakova; Jobert G Barin; G Christian Baldeviano; Miho Kimura; Monica V Talor; Daniel H Zimmerman; Eyal Talor; Noel R Rose
Journal:  Int Immunopharmacol       Date:  2008-01-29       Impact factor: 4.932

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.